Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02954172
Other study ID # CIBI305A301
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 28, 2016
Est. completion date November 12, 2019

Study information

Verified date November 2020
Source Innovent Biologics (Suzhou) Co. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, double blind, multicenter phase3 study .


Description:

A randomized, double blind, multicenter phase3 study in chemotherapy naive patients with stage IIIB,IV or recurrent NSCLC of non-squamous. the study will randomize about 436 patients at a 1:1 ratio to 2 treatment arms. The study is divided 4 phase, screening, combination treatment, maintenance and follow up.


Recruitment information / eligibility

Status Completed
Enrollment 450
Est. completion date November 12, 2019
Est. primary completion date October 19, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. signed inform consent form(ICF) 2. Age = 18 years and = 75 years, male or female 3. Histologically or cytologically documented inoperable, local advanced (stage IIIB), metastatic (stage IV), or recurrent non-squamous NSCLC; Mixed tumors should be categorized according to the predominant cell type 4. Histologically confirmed epidermal growth factor receptor (EGFR) wild type or insensitive mutation 5. At least one measurable lesion according to Response Evaluation Criteria In Solid Tumors(RECISIT) v 1.1 6. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1 7. Life expectancy = 6 months 8. Laboratory results: 1. Adequate hematologic function, defined as absolute neutrophil count =1.5×10^9 /L, platelet count =100 ×10^9 /L, hemoglobin =90g/L; 2. Adequate liver function, defined as total bilirubin levels = 1.5 times normal upper limit (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels = 2.5 times ULN, or AST and ALT levels = 5 times ULN for patients with hepatic metastasis; 3. Adequate renal function, defined as serum creatinine = 1.5 times ULN or creatinine clearance = 50 ml / min (Cockcroft-Gault formula) and proteinuria < 2+; 4. Coagulation function is adequate, defined as international normalized ratio (INR) or prothrombin time (PT) = 1.5 times normal upper limit (ULN), PTT or aPTT = 1.5 times ULN; 9. Expected protocol compliance 10. Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for 6 months after receiving last study treatment (e.g. abstinence, sterilization surgery, oral contraceptives, contraception by progesterone injection or subcutaneous). Exclusion Criteria: 1. Prior chemotherapy or target therapy with another systemic anti-cancer agent (e.g., monoclonal antibody, tyrosine kinase inhibitor) for the treatment of the patient's current stage of disease (Stage IIIB not amenable for combined modality treatment, stage IV or recurrent disease). Prior surgery and irradiation is permitted, provided that the criteria outlined in the protocol for both treatments are met. Disease progressed within 6 months after adjuvant therapy must be excluded. 2. Mixed non-small cell and small cell carcinoma, or mixed adenosquamous carcinomas with predominant squamous cell 3. Histologically or cytologically confirmed EGFR sensitive mutation type, unknown EGFR status for any reason is allowed in this study. 4. Known hemoptysis within 3 months prior to screening with blood volume more than 2.5 mL each time 5. Evidence of tumor invading major blood vessels on imaging. The investigator or the local radiologist must exclude evidence of tumor that is fully contiguous with, surrounding, or extending into the lumen of a major blood vessel (e.g., pulmonary artery or superior vena cava) 6. Evidence of brain metastasis, spinal cord compression or carcinomatous meningitis history with clinical symptoms. For stable patients with no symptom, could be admitted if fulfill all below criteria: measurable lesion(s) out of CNS, no metastasis at mesocephalon, annular protuberance, medulla oblongata and spinal cord; no history of intracranial bleeding. 7. Radical radiotherapy to the thorax with curative intent within 28 days prior to enrollment; palliative radiotherapy for bone lesions outside the thoracic region within 2 weeks prior to first dose of study treatment. 8. Serious, non-healing wound, active ulcer, or untreated bone fracture, or major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of the study. 9. Minor surgery (Including insertion of an indwelling catheter) within 48 hours prior to first dose of study treatment 10. Recent or current (within 10 days prior to first dose of study treatment) receive treatment of Aspirin (> 325 mg/day) or other non-steroidal anti-inflammatory drugs (NSAID) known to inhibit platelet function (within 10 days prior to first dose of study treatment) 11. Recent or current receive treatment of oral all doses of oral or parenteral anticoagulants or thrombolytic agent. Prophylactic use of anticoagulants is permitted. 12. History or evidence of inherited bleeding diathesis or coagulopathy or thrombus 13. Uncontrolled hypertension (SBP>140 mmHg and/or diastolic blood pressure>90 mmHg), prior history of hypertensive crisis and hypertensive encephalopathy 14. Clinically significant cardiovascular disease but not limited to active infections; unstable angina; stroke or transient cerebral ischemia (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening) ; congestive heart-failure (New York Heart Association (NYHA) class= II) ; serious cardiac arrhythmia, hepatic, renal or metabolic disease requiring medication during the study. 15. History of peptic ulcer, gastrointestinal perforation, erosive esophagitis, erosive gastritis, inflammatory bowel disease or diverticulitis, abdominal fistula or intra-abdominal abscess within 6 months prior to screening 16. Patient diagnosed with a tracheo-esophageal fistula 17. Clinically significant third space effusion (e.g., uncontrolled ascites or pleural effusion by extraction or other treatment) 18. Pulmonary fibrosis or active pneumonia showed by CT at baseline 19. Active malignancy other than non-small cell lung cancer (NSCLC), treated carcinoma in situ of the cervix, superficial basal cell or squamous cell carcinoma, radical surgery of localized prostate cancer, radical surgery of ductal carcinoma in situ within 5 years prior to randomization 20. Known autoimmune disease 21. Known positive HbsAg and hepatitis B virus (HBV)-DNA drop test in peripheral blood = 1 x 10^3 copy number/L or 200 IU/mL; If HBsAg positive and HBV-DNA drop test in peripheral blood < 1 x 10^3 copy number/L or 200 IU/mL, patient is considered to be eligible by investigator only when chronic hepatitis B in the plateau and do not increase the risk 22. Known positive HIV or hepatitis C virus (HCV) or syphilis 23. Known allergic disease or allergic physique 24. Treatment with any other investigational agent or participation in another clinical trial within 30 days prior to screening 25. Known alcoholism or drug abuse 26. Pregnant or anticipation of pregnant during the study or lactating women 27. Known hypersensitivity to bevacizumab or any of its excipients and/or any of the chemotherapy agents 28. Other conditions that the investigator thinks unsuitable in this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bevacizumab in Combination With Paclitaxel/Carboplatin
Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
IBI305 in Combination with Paclitaxel/Carboplatin
Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

Locations

Country Name City State
China Cancer Center; Sun Yat sen University; Guangzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Innovent Biologics (Suzhou) Co. Ltd. WuXi CDS Clinical Research (Shanghai) Co.Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate ORR(objective response rate)was defined as the percentage of participants in the analysis population who had a Complete Response or a Partial Response per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Overall Response (OR) = CR + PR. 18 weeks
Secondary Overall Survival Time OS was defined as the time from randomization to death due to any cause. 18.020 months
Secondary Progression-free Survival Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by Independent Radiological Review Committee.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT05821933 - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC Phase 1/Phase 2
Active, not recruiting NCT03269162 - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection Phase 3
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT06315686 - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Recruiting NCT05466149 - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT03609918 - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting NCT06043817 - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05078931 - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients Phase 2
Not yet recruiting NCT05547737 - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn NCT05959473 - EGFR_IUO 3.20 Clinical Study Protocol N/A
Not yet recruiting NCT05005468 - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Phase 2
Recruiting NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease Phase 2
Completed NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2